CLEARPOINT NEURO Business Summary

ClearPoint Neuro Inc. (CLPT) operates a specialized medical device and services business model centered on its proprietary MRI-guided neuro-navigation platform. The company generates revenue through a high-margin "razor-and-blade" strategy, selling capital equipment (ClearPoint Neuro Navigation System), recurring single-use disposables (SmartFrames and SmartFlow cannulas), and multi-year software licenses. Its operations are divided into four primary segments: Neurosurgery Navigation, Biologics & Drug Delivery, Laser Therapy and Access, and Intracranial Fluid Management—the latter significantly expanded following the late 2025 acquisition of IRRAS and its IRRAflow product line. ClearPoint competes directly with medical technology giants such as Medtronic, Boston Scientific, and Integra LifeSciences, as well as niche players like BrainsWay. Within this landscape, ClearPoint distinguishes itself as the premier "picks and shovels" provider for the central nervous system (CNS) gene and cell therapy market, serving as the essential delivery infrastructure for over 60 biopharma partners. Originally founded in 1998 as Surgi-Vision by a pioneering team of Johns Hopkins University researchers—including Dr. Paul Bottomley, Dr. Elias Zerhouni, Dr. Ergin Atalar, and Dr. Henry Halperin—the company is currently led by President and CEO Joseph Burnett, a former executive at Philips and Volcano Corporation. The leadership team includes CFO Danilo D’Alessandro, also a Philips veteran, and Chief Medical Officer Dr. Paul S. Larson, an internationally recognized functional neurosurgeon who joined the executive ranks in January 2026. The company’s strategic direction is overseen by Chairman R. John Fletcher and a board featuring prominent neurosurgeon Dr. Linda M. Liau. Notable institutional backing includes significant positions from BlackRock, Vanguard, and Prescott Group Capital Management, reflecting strong investor confidence in the company’s transition from a surgical tool manufacturer to a comprehensive neuro-therapeutic platform.